SPYVLP01

About SpyBiotech

SpyBiotech is a private, clinical-stage biotech pioneering a versatile vaccine platform technology centered on the SpyTag/SpyCatcher protein ligation system. This 'plug-and-play' approach allows for the efficient and irreversible conjugation of target antigens to various delivery platforms, aiming to generate stronger and more targeted immune responses. The company's lead program is a Phase I cytomegalovirus (CMV) vaccine candidate, with a broader pipeline exploring applications in viral, bacterial, and parasitic diseases, as well as oncology. SpyBiotech's ambition is to address major unmet medical needs by accelerating and simplifying vaccine development.

Therapeutic Areas